Emphysema - Pipeline Review, H2 2011

Global Markets Direct, November 2011, Pages: 45

Emphysema - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Emphysema - Pipeline Review, H2 2011', provides an overview of the Emphysema therapeutic pipeline. This report provides information on the therapeutic development for Emphysema, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Emphysema. 'Emphysema - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Emphysema.
- A review of the Emphysema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Emphysema pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Emphysema.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Emphysema pipeline depth and focus of Emphysema therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Emphysema Therapeutic Products under Development, Key Players in Emphysema Therapeutics, Emphysema Pipeline Overview, Emphysema Pipeline, Emphysema Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Emphysema Overview
Therapeutics Development
An Overview of Pipeline Products for Emphysema
Emphysema Therapeutics under Development by Companies
Emphysema Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Emphysema Therapeutics - Products under Development by Companies
Emphysema Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Emphysema Therapeutics Development
F. Hoffmann-La Roche Ltd.
Sangamo BioSciences, Inc.
Talecris Biotherapeutics Holdings Corp
Kamada Ltd.
Applied Genetic Technologies Corporation
Intrexon Corporation
Emphysema - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
RG667 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aerosolized AAT - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Alpha1-Proteinase Inhibitor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rAAV1-CB-hAAT - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mesenchymal Stromal Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Alpha 1-antitrypsin + rHuPH20 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ZFN-Corrected iPSCs - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Emphysema Therapeutics – Drug Profile Updates
Emphysema - Featured News
Oct 13, 2011: Sangamo Announces Publication In Nature of Gene Correction Strategy For Alpha 1-Antitrypsin Deficiency
Oct 11, 2011: Isis Selects Isis-AATRx To Treat AATD-Associated Liver Disease
Mar 23, 2011: Novartis Announces FDA Extension For Regulatory Review Period For QAB149
Feb 14, 2011: Kamada Announces Successful Interim Report Of Phase II-III Clinical Trial With Inhaled Alpha-1 Antitrypsin
Oct 25, 2010: Baxter Launches GLASSIA In US
Oct 25, 2010: Baxter Launches GLASSIA In US
Oct 12, 2010: BioRx Enters the Alpha-1 Specialty Home Infusion Market
Aug 26, 2010: Baxter International Inc. acquires exclusive right to distribute Kamada’s Glassi alpha-1 augmentation therapy in Canada
Aug 26, 2010: Baxter International Inc. acquires exclusive right to distribute Kamada’s Glassi alpha-1 augmentation therapy in Canada
Aug 24, 2010: Baxter Announces Manufacturing, Supply and Distribution Agreement with Kamada for Glassia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Emphysema, H2 2011
Products under Development for Emphysema – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
F. Hoffmann-La Roche Ltd., H2 2011
Sangamo BioSciences, Inc., H2 2011
Talecris Biotherapeutics Holdings Corp, H2 2011
Kamada Ltd., H2 2011
Applied Genetic Technologies Corporation, H2 2011
Intrexon Corporation, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Emphysema Therapeutics – Drug Profile Updates

List of Figures
Number of Products under Development for Emphysema, H2 2011
Products under Development for Emphysema – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Customers who bought this item also bought

• Emphysema Global Clinical Trials Review, H2, 2012
• Emphysema Global Clinical Trials Review, H2, 2011
• Emphysema - Pipeline Review, H1 2012
• Psoriasis - Pipeline Review, H2 2012
• Acute Pain - Pipeline Review, H2 2012
• Emphysema - Pipeline Review, Q2 2011
• Obstructive Pulmonary Disease - Pipeline Review, H2 2012
• Rheumatoid Arthritis - Pipeline Review, H2 2012
• Pulmonary Fibrosis - Pipeline Review, H2 2012
• Smoking Cessation - Pipeline Review, H2 2012